RALY may cause an aggressive biological behavior and a dismal prognosis in non-small-cell lung cancer
- 1 April 2020
- journal article
- research article
- Published by Elsevier in Experimental Cell Research
- Vol. 389 (2) , 111884
Abstract
No abstract availableKeywords
Funding Information
- Clinical Capability Construction Project for Liaoning Provincial Hospitals (LNCCC-B08-2014)
This publication has 33 references indexed in Scilit:
- c-Myc suppresses microRNA-29b to promote tumor aggressiveness and poor outcomes in non-small cell lung cancer by targeting FHITOncogene, 2014
- Euphol arrests breast cancer cells at the G1 phase through the modulation of cyclin D1, p21 and p27 expressionMolecular Medicine Reports, 2013
- Proteome-Wide Characterization of the RNA-Binding Protein RALY-Interactome Using the in Vivo-Biotinylation-Pulldown-Quant (iBioPQ) ApproachJournal of Proteome Research, 2013
- NONO and RALY proteins are required for YB-1 oxaliplatin induced resistance in colon adenocarcinoma cell linesMolecular Cancer, 2011
- RhoA and RhoC have distinct roles in migration and invasion by acting through different targetsJournal of Cell Biology, 2011
- Biomarkers for epithelial-mesenchymal transitionsJournal of Clinical Investigation, 2009
- The many faces of c-MYCArchives of Biochemistry and Biophysics, 2003
- p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21Cell, 1994
- A molecular model for the genetic and phenotypic characteristics of the mouse lethal yellow (Ay) mutation.Proceedings of the National Academy of Sciences, 1994
- The embryonic lethality of homozygous lethal yellow mice (Ay/Ay) is associated with the disruption of a novel RNA-binding protein.Genes & Development, 1993